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Abstract
There is an urgent need for novel antibiotics to treat life-threatening infections caused by bacterial
‘superbugs’. Validated in vitro pharmacokinetic/pharmacodynamic (PK/PD) and animal infection
models have been employed to identify the most predictive PK/PD indices and serve as key tools
in the antibiotic development process. The results obtained can be utilized for optimizing study
designs in order to minimize the cost and duration of clinical trials. This review outlines the key in
vitro PK/PD and animal infection models which have been extensively used in antibiotic
discovery and development. These models have shown great potential in accelerating drug
development programs and will continue to make significant contributions to antibiotic
development.
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Introduction
Rapidly increasing antibiotic resistance and the lack of new antibiotics in the drug discovery
pipeline are presenting a significant unmet global medical need [1]. Antimicrobial resistance
has been identified as one of the three greatest threats to human health. An urgent global call
for the discovery of new antibiotics, The 10 × ‘20 Initiative, has been made recently [1]. In
antibiotic discovery and development, pharmacokinetic/pharmacodynamic (PK/PD) and
animal infection models play essential roles and bridge the gap between in vitro
susceptibility and clinical evaluations of new antibiotics. Identification of PK/PD
relationships in an early discovery stage provides a quantitative tool to enable rational go or
no-go decision making and predictions of clinical pharmacological profiles of superior
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leads. This review outlines the key PK/PD models that have been extensively used in
antibiotic discovery and development.
In vitro PK/PD models
In vitro PK/PD models essentially fall into one of two categories: one-compartment or two-
compartment models (Figure 1) [2,3]. One-compartment models typically consist of a
central reservoir containing the organism, a diluent reservoir and a waste reservoir. Drug is
administered to the central reservoir with drug elimination achieved by pumping drug-free
media into the central reservoir; this setup, while necessary for mimicking the PK of
antibiotics in patients (i.e. simulation of the desired antibiotic half-life), simultaneously
eliminates bacteria. This unintended consequence can be problematic for antibiotics with
short elimination half-lives and is the primary disadvantage of one-compartment PK/PD
models. To overcome this problem filters have been utilized to prevent bacterial loss, but are
prone to blockage [4].
Two-compartment PK/PD models are similar to one-compartment models, but prevent
bacterial elimination by physically separating bacteria from the central reservoir within a
small peripheral compartment (typically 10 – 20 mL). The most common example is the
hollow fiber infection model (HFIM) containing thousands of small tubular fibers (filters) in
a cartridge through which medium is pumped [5]. Pores on the fibers retain the
microorganisms while allowing the free diffusion of drugs and other molecules (e.g.
glucose). Drug is administered into, and eliminated from, the central reservoir with
antibiotic concentrations equilibrating rapidly with the peripheral (bacterial containing)
compartment. Importantly, both absorption and elimination kinetics of the antibiotic under
investigation can be precisely and independently controlled. The versatility of both one- and
two-compartment models allows for the simulation of virtually any desired elimination half-
life observed in patients.
These PK/PD models have played an important role in the determination of the key PK/PD
indices driving antibacterial activity (i.e. Cmax/MIC [the peak concentration divided by the
MIC], AUC/MIC [the area under the concentration-time curve over 24 h in steady-state
divided by the MIC] or T>MIC [the cumulative percentage of a 24-h period that the drug
concentration exceeds the MIC at steady-state pharmacokinetic conditions]) [2].
Identification of the most predictive PK/PD index and the associated values required for
different magnitudes of killing is essential for the rational design of optimal dosing
strategies in animal and clinical studies. Dose-fractionation studies in in vitro PK/PD models
are more easily performed than in animal models. A recent example is the work by Bergen
et al. that identified AUC/MIC as the main driver of antibacterial activity for colistin [6].
This information subsequently contributed to the first scientifically-based dosing guidelines
for colistin in critically-ill patients [7]. Such in vitro dose-fractionation is increasingly
applied to dosage regimen optimization of other antibiotics [8]. The PK/PD information
obtained is crucial for designing optimal dosing strategies for further evaluations in animal
models and clinical trials.
In vitro PK/PD models are also increasingly being used in the assessment of the emergence
of resistance with mono- and combination antibiotic therapy [9–12], and demonstrate that
emergence of resistance is a complex interplay of the PK and PD of antibiotics [13,14]. Thus
the PK profiles simulated in PK/PD models provide more clinically relevant information
than static models. The utility of PK/PD models in this regard is exemplified in the study by
Tam et al [13]. Using a hollow fiber infection model, it was demonstrated that, in a
heterogeneous bacterial population with multiple subpopulations of varying drug
susceptibility, low to medium exposures (based on AUC/MIC) of quinolones selectively
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amplified resistant subpopulation(s) whereas high drug exposures suppressed this. Bergen et
al. demonstrated that of three dosage regimens each providing a similar exposure to colistin,
emergence of resistance was substantially greater and occurred earlier with the two colistin
regimens employing the longer dosage intervals [15]. Additionally, in vitro PK/PD models
have been employed to identify antibiotic breakpoints deemed crucial for suppression of
resistance development [16].
In addition to being less cost- and resource-intensive, in vitro PK/PD models permit
investigations of considerable duration (e.g. weeks) that may not be feasible in animals.
Furthermore, PK/PD models allow for the use of high inocula without the ethical concerns
associated with excessive early mortality of the animals; the latter is particularly important
for the investigation of resistance development as a high bacterial load (e.g. 108 CFU/mL) is
usually required to increase the probability of detection of resistant mutants [14]. In
addition, these models can be used to examine microorganisms for which animal models are
not well established. Results obtained from in vitro PK/PD models have shown good
correlations with human and animal data [17,18]. The lack of immune components in in
vitro models is both a limitation and an advantage. While this presents difficulties in
extrapolating results to immunocompetent hosts, in vitro models permit the direct evaluation
of the activity of antibiotics themselves in the absence of host defenses, mimicking the
situation in the immunocompromised. It is for this reason that PK/PD models have been
particularly useful in the study of anti-tubercular drugs [18].
In summary, in vitro PK/PD studies provide important insight into the therapeutic potential
of lead compounds in early antibiotic development, and assist in the design of optimal
dosage strategies for animal studies and clinical trials.
In vitro biofilm models
Microorganisms are frequently biofilm-embedded in nature and also in the clinic such as in
catheter or prosthetic joint infections, chronic sinusitis and infective endocarditis [19].
Biofilm can result in increased antimicrobial tolerance by altering bacterial metabolism,
retarding the diffusion of antibiotics, increasing the enzymatic-inactivation of antibiotics in
the extracellular matrix, and impairing bacterial clearance by the immune system [19]. In in
vitro biofilm models, factors including restriction of nutrients and oxygen, surface material,
shearing force and the age of the biofilm may significantly influence the maturity of the
biofilm and its response to antimicrobials [20–22]. The classic concepts of MIC and
minimal bactericidal concentration for planktonic cells have a poor clinical correlation in a
biofilm scenario. Minimal biofilm inhibitory (MBIC) and eradicative concentrations
(MBEC) more accurately reflect the activity of antimicrobials in biofilm [23].
Measurements of MBIC and MBEC can be achieved by microtiter plate-based models using
automatized technology. The Calgary device [23] has been widely used, and numerous
variations (e.g. addition of magnetic beads to the media used in the Biofilm Ring Test [24]
or microcalorimetric assays [25]) have been recently incorporated into this static biofilm
model. However, for examining the anti-biofilm PK/PD of antibacterials, dynamic models
are required to mimic antibacterial PK in vivo. In the plug flow reactors, microbiological
broth flows in one direction and solutes diffuse in a radial direction [21]. Another recent
development is the drip flow biofilm reactor that is able to grow biofilm under low shearing
forces [21]. Similarly, microfluidic devices (e.g. BioFlux) allow multiple parallel
experiments for growing biofilm under low flow rates and shearing forces [22]. In
continuous flow stirred tank reactors, homogenous mixing and diffusion of solutes occurs
throughout the reactor [20]. Two representative examples are the Rotating Disk Reactor [26]
and the CDC Biofilm Reactor [27]. In addition, in these models imaging techniques (e.g.
advanced fluorescence microscopy and integrated nuclear magnetic resonance and confocal
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laser scanning microscopy) are commonly used for evaluating antimicrobial diffusion, and
changes in the biofilm ultra-structure and on viable but non-culturable bacteria after
antibiotic treatment [28–30].
Animal infection models
Animal infection models serve an important role in simulating the pathophysiology of
infections in patients and as a platform for preclinical assessments of new antibiotics, as well
as optimizing antibiotic use [31]. Pertaining to this review, animal models have been
instrumental for evaluating antimicrobial PK/PD, notably the relationships between in vitro
activity, bacterial growth, size of the inoculum, the timing of treatment, PK and in vivo
efficacy [32]. Disadvantages of animal models include the variations in the PK of antibiotics
compared to that in humans. In attempts to simulate human PK and usually prolong the half-
life of the drug in animals, multiple doses or inducing transient renal impairment in animals
by administration of uranyl nitrite can be employed [33]. In addition, allometric scaling
should be considered when designing dosage regimens in animals. This section provides a
practical overview of the most commonly used animal models in antibiotic drug discovery.
Thigh infection models
The mouse thigh infection model is the most common animal model to examine antibiotic
PK/PD relationships [33,34]. The model is relatively inexpensive and reproducible. Mice are
rendered neutropenic by treatment with cyclophosphamide on days -4 and -1, producing
neutropenia by day 0 [33,34]. Log-phase bacterial cells (normally 105–106 colony forming
units [CFU], depending on bacterial strains) are injected into each thigh under light
anesthesia. An important consideration is the time difference between inoculation and the
commencement of therapy. The tested compound is administered over 24 h with multiple
dosing regimens depending on the half-life and the PK/PD indices under investigation. The
efficacy of the antibacterial agent is commonly determined by subtracting the log10 CFU/
thigh at 24 h of the treated mice from that of the control mice at 0 h. PK/PD indices of
T>MIC, AUC/MIC or Cmax/MIC can be related to the in vivo efficacy, most commonly by a
sigmoid model [34]. Notable examples of the application of the mouse thigh infection model
to study PK/PD relationships for antibiotic development include cephalosporin PPI-0903
[35] and linezolid [36]. In the linezolid study, it was revealed that a dosage regimen of 600
mg twice daily (AUC/MIC of 50 to 100) would be effective against pathogens with MICs as
high as 2 to 4 mg/L [36].
Septicemia models
This model has been instrumental for in vivo efficacy of numerous antibiotics [37,38]. The
model has been implemented across a number of animal species; however, for reasons of
economy mice and rats are most commonly used. The simplicity of the endpoint analysis
lends the mouse septicemia model to the routine use for preclinical in vivo efficacy
assessment of novel antimicrobials [38]. For mice, in most instances, the model involves
rendering the animal neutropenic through the administrations of 100–150 mg/kg of
cyclophosphamide once a day for 3 days. The unanesthetized animal is then infected by an
intraperitoneal injection of 0.1–0.5 mL of a log-phase bacterial suspension. Antibiotic(s) is
administered by subcutaneous injection 1 h postinoculation over multiple dosage regimens
for a period of up to 72 h. Other drug administration routes can be used depending on the
prospective formulation of the compound. Endpoints for this model can be morbidity (%
survival) and bacterial load (CFU) in the blood. Compared to the thigh infection model, the
mouse septicemia model is significantly less time consuming and labor intensive as tissue
homogenization and filtration are not required for viable counting.
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Bacterial endocarditis can be a very difficult infection to treat due to inaccessibility of
organisms within the core of the vegetations to the immune system and poor penetration of
antibiotics into the infected endocardial vegetations [39]. The latter can also set ideal
conditions for bacteria to develop resistance. Moreover, bacteria within the core of the
vegetations display low metabolic activity rendering them less susceptible to antibiotics
[40]. Endocarditis animal models have been developed in several species including mouse,
rat, rabbit, pig, dog and opossum [41]. Endpoints used in this model include CFU/vegetation
and morbidity; blood samples are also collected to test for sepsis and relapse of infection
following treatment. Endocarditis models have been extensively used for antibacterial PK/
PD studies [41]. For fluoroquinolones, it was reported that an AUC/MIC ≥100 is required
for bacterial clearance over 3–6 days of therapy [41].
Urinary tract infection (UTI) models
UTI is a significant urologic disease in women, predominantly caused by uropathogenic
Escherichia coli from the intestinal flora that colonize the urethra and bladder [42]. UTI may
even ascend from the bladder to the kidneys causing permanent damage and scarring [43].
Several animal models of ascending unobstructed UTI have been developed for antibacterial
pharmacology and discovery [44]. Female mice are routinely used to simulate ascending
UTI in women; however, male mice can also be employed [45]. After the animal is
anesthetized, a catheter is inserted into the urethra and a needle is inserted into the catheter
opening through which ~50 μL of bacterial suspension is delivered (usually 107–109 CFU/
mouse). The mouse should not be given liquids for 1 h prior to and after bacterial challenge
to reduce urine output. Careful attention should be paid to the growth media used for
preparation of the inoculum as certain medium conditions provide for the expression of
virulence factors required for uropathogenesis. The infection usually peaks one day post
challenge and resolves over 2–3 weeks, depending upon the bacterial strain, the genetic
background of inbred mice, and the absence of inoculation-associated vesicoureteral reflux.
The endpoints are usually bacterial cultures of bladder and kidney homogenates. Additional
parameters monitored may include morbidity and blood cultures, while homogenates of liver
and spleen can also be taken to monitor dissemination of the infection outside the urinary
tract. The mouse UTI model was recently employed to demonstrate the in vivo efficacy of
ACHN-490, a new aminoglycoside with good in vitro activity against MDR Gram-negative
and select Gram-positive pathogens [38]. ACHN-490 treatment (0.125–8 mg/kg/12 h for 3
days) effectively reduced log10CFU counts in the kidneys, bladder and urine of treated
animals [38].
Wound infection models
Infection remains the major cause of morbidity in wound patients worldwide [46].
Numerous external traumatic wound infection models have been developed to simulate
various forms of traumatic injury and evaluate antibacterial treatment [46]. Examples of
animal wound infection models include skin abrasions, burns and excision wounds. Albino
Hartley guinea pigs are typically used for wound models; their dorsal hair is clipped and a
black grid is drawn on the back of the animal where the lesions are created. The main factors
which determine the severity of the traumatic wound infection model include bacterial
inoculum, size of the wound and immune-competence of the animals. The end-point for
these models usually includes histopathological examination of sections of lesions and
counting of viable bacteria recovered from the inoculation sites to determine the inoculation
producing 50% probability of infection (ID50). ID50 values are determined by logistic
regression from a plot of the infection rate versus the bacterial inoculum size, and can be
employed to access the efficacy of antibacterial agents. The assessment of antibacterial
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agents in wound models has generally yielded good correlation between their in vitro
activity and in vivo efficacy in humans [47].
Animal biofilm models
Several biofilm-related animal models have been developed with or without the addition of
foreign material, including central venous catheter models, subcutaneous foreign body
infection models and osteomyelitis infection models [20]. The infection may be established
by direct inoculation into a specific organ or space (e.g. the otitis media model),
manipulation of the infection site (e.g. cortical bone drilling before inoculation in
osteomyelitis models), or implantation of a foreign body (e.g. device-related osteomyelitis)
[20]. The microorganisms inoculated are usually planktonic but capable of attaching to
surfaces and developing biofilm. Sessile biofilm-embedded microorganisms have also been
used for inoculation to mimic specific clinical scenarios [48]. Recently, an in vivo
polymicrobial biofilm wound infection model was developed to study interspecies
interactions in biofilm and their relation to wound chronicity [49].
In addition, a number of recent animal infection models have been adapted for the real-time
monitoring of infections using luminescent bacteria [50,51]. This allows for the monitoring
of infections in live animals in a non-invasive manner. Nevertheless, the sensitivity of
bioluminescence is generally lower compared to viable counting methods; hence, such
models may not be able to differentiate a marked bactericidal action from mild antibacterial
effect.
Antimicrobial PK/PD modeling
State-of-the-art data analysis to optimize the data gained from the in vitro and animal
models is critical for antibiotic development. Traditional PK/PD target approaches aim to
maximize T>MIC, AUC/MIC or Cmax/MIC with the targets for stasis and different
magnitudes of bacterial killing derived from pre-clinical models. Combined with population
PK modeling, the PK/PD target approach allows the prediction of the likelihood of target
attainment in a patient population (including for dosage regimens not previously studied in
clinical trials) [52]. More recently, mechanism-based mathematical (MBM) models [53]
have been developed to incorporate (a) multiple biologically relevant mechanisms (e.g.
antibacterial action and resistance), (b) concentration-time courses of single or multiple
antibiotics, (c) effects of antibiotic exposure on bacterial killing and emergence of resistance
in heterogeneous bacterial sub-populations with different antibiotic susceptibilities, and (d)
effects of the immune system. Based on in vitro PK/PD data (e.g. hollow fiber infection
model), MBM models can establish a quantitative relationship between PK profiles in
patients and the time course of bacterial killing and resistance for further pre-clinical and
clinical evaluations.
Conclusion
One of the significant challenges in antibiotic development is to establish the correlation
between in vitro susceptibility and clinical efficacy. Hence, validated in vitro PK/PD and
animal infection models serve as key tools in the antibiotic development process and have
been widely employed for identifying the most predictive PK/PD indices. After analysis
using comprehensive mathematical modeling, the results obtained set a quantitative basis for
optimizing study designs in order to minimize the cost and duration of expensive clinical
trials. In summary, in vitro PK/PD and animal infection models have shown great potential
in increasing success rates and accelerating the drug development process, and will continue
to make a significant contribution to the search for new antibiotics.
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MIC minimum inhibitory concentration




AUC/MIC the area under the concentration-time curve over 24 h in steady-state divided
by the MIC
Cmax/MIC the peak concentration divided by the MIC
T>MIC the cumulative percentage of a 24-h period that the drug concentration
exceeds the MIC at steady-state pharmacokinetic conditions
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• In vitro PK/PD models are less cost- and resource-intensive and permit
investigations of considerable duration not feasible in animals.
• Mouse thigh infection model is the gold standard for antibacterial PK/PD.
• Animal infection models play a critical role in the preclinical assessment of
novel antibiotics.
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In vitro PK/PD models. (A) The one-compartment model. The volume remains constant but
the test organism is not constrained. (B) Hollow fiber two-compartment model. Bacterial
cells reside in the hollow fiber cartridge. The nutrient broth continually re-circulates through
the central reservoir and cartridge. Drug is administered to the central reservoir and the
elimination kinetics is controlled by the addition of fresh drug-free medium to the central
reservoir. Figures adapted from reference [5] with permission.
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